Electromedical Technologies, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsElectromedical Technologies, Inc. is a small, loss-making medical device company focused on electrotherapy devices, trading over-the-counter under EMED.
What they do
The company develops and markets electrotherapy devices for pain management and wellness. It sells through direct and distributor channels. Its corporate offices are in Scottsdale, Arizona.
Revenue drivers
- Electrotherapy device sales — Revenue comes from sales of electrotherapy devices, primarily the BioElectroMed line. Annual revenue has been between $0.7 million and $1.3 million in recent years.
Recent performance
Revenue for the nine months ended September 30, 2024 was $570,415, down from $1,081,240 in the same period of 2023. The third quarter of 2024 saw revenue of only $42,526, a sharp decline from $351,595 in the fourth quarter of 2023. Net loss for the nine months ended September 30, 2024 was $1,453,504, compared to $1,749,243 in the prior year period. The company had $34,809 in cash and a working capital deficit of $3.8 million as of September 30, 2024.
Strategy
Management has not publicly outlined a detailed growth strategy in the provided filings. Recent 8-K events include changes to the charter and bylaws, a change in accountants, and a change in control in February 2023. The company continues to operate with minimal cash and relies on financing to fund operations.
Risks
- Going concern — The company has a stockholders' deficit of $4.0 million and limited cash, raising substantial doubt about its ability to continue as a going concern.
- Revenue decline — Revenue in the third quarter of 2024 fell to $42,526, a significant drop from prior quarters, indicating potential loss of customers or market traction.
- Regulatory and reimbursement — As a medical device company, changes in FDA regulation or insurance reimbursement could adversely affect sales.
- Dilution and financing — The company has a history of net losses and negative operating cash flow, and may need to raise additional capital, potentially diluting existing shareholders.
Outlook
The company has not provided specific guidance in the provided excerpts. Management's focus appears to be on maintaining operations and addressing financial reporting deficiencies, as evidenced by the 10-K/A filing to correct certification language.